JPMorgan Chase & Co. Has $57.38 Million Position in Haleon plc (NYSE:HLN)

JPMorgan Chase & Co. lifted its position in shares of Haleon plc (NYSE:HLN) by 18.3% during the 4th quarter, Holdings Channel reports. The firm owned 6,014,903 shares of the company’s stock after purchasing an additional 930,701 shares during the quarter. JPMorgan Chase & Co.’s holdings in Haleon were worth $57,382,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently modified their holdings of HLN. Addison Advisors LLC grew its holdings in Haleon by 28.7% during the fourth quarter. Addison Advisors LLC now owns 4,954 shares of the company’s stock worth $47,000 after purchasing an additional 1,106 shares during the period. Synovus Financial Corp boosted its stake in shares of Haleon by 0.8% during the 3rd quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock worth $1,575,000 after acquiring an additional 1,216 shares during the period. Haverford Trust Co increased its holdings in shares of Haleon by 5.0% during the 4th quarter. Haverford Trust Co now owns 25,842 shares of the company’s stock worth $247,000 after acquiring an additional 1,233 shares during the last quarter. Greenleaf Trust raised its stake in Haleon by 8.4% in the 4th quarter. Greenleaf Trust now owns 17,225 shares of the company’s stock valued at $164,000 after acquiring an additional 1,333 shares during the period. Finally, Baron Wealth Management LLC lifted its holdings in Haleon by 4.3% during the 4th quarter. Baron Wealth Management LLC now owns 33,632 shares of the company’s stock valued at $321,000 after purchasing an additional 1,381 shares during the last quarter. 6.67% of the stock is owned by institutional investors.

Haleon Stock Performance

Shares of NYSE:HLN opened at $9.89 on Friday. Haleon plc has a 12-month low of $7.99 and a 12-month high of $10.80. The company’s 50 day moving average price is $10.03 and its two-hundred day moving average price is $9.87. The firm has a market cap of $44.75 billion, a PE ratio of 29.07, a PEG ratio of 2.82 and a beta of 0.25. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last issued its quarterly earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion for the quarter, compared to the consensus estimate of $3.38 billion. Equities research analysts predict that Haleon plc will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The business also recently declared a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a $0.1166 dividend. The ex-dividend date of this dividend is Friday, April 25th. This represents a dividend yield of 1.6%. This is a boost from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

Wall Street Analysts Forecast Growth

HLN has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. Finally, HSBC restated a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Six analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Haleon presently has an average rating of “Hold” and a consensus target price of $10.95.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.